ReviewWorld journal of diabetes2024
Tuberculosis-diabetes comorbidities: Mechanistic insights for clinical considerations and treatment challenges.
Review in World journal of diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Complex Disseminated Tuberculosis with Oral and Gastrointestinal Involvement: Histopathologic and Clinical Insights.Diagnostics (Basel, Switzerland) · 2026Article
- Influence of Diabetes Mellitus on the Development of Multidrug-Resistant Tuberculosis (MDR-TB) in Relation With Genetic Mutations ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- The eight pillars of within-host tuberculosis modelling.Frontiers in immunology · 2026Review
- Glucose driven bacterial persistence in extensively drug-resistant tuberculosis with diabetes.Frontiers in public health · 2026Article
- Predictive Factors for Progression to Severe Pulmonary Tuberculosis in Patients with Concurrent HIV/AIDS and Type 2 Diabetes Mellitus: A Single-Center Retrospective Study.Infection and drug resistance · 2026Article
- Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance.Pharmaceutics · 2025Review
- Dual Burden of MDR-TB and COVID-19 in a Previously Treated Tuberculosis Case: Diagnostic and Therapeutic Dilemmas.Clinical case reports · 2025Article
- Article
- Enhancing metformin efficacy with cholecalciferol and taurine in diabetes therapy: Potential and limitations.World journal of diabetes · 2025Article
- The role of metformin in tuberculosis control among TB and diabetes mellitus comorbid individuals.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a leading cause of death among infectious diseases, particularly in poor countries. Viral infections, multidrug-resistant and ex-tensively drug-resistant TB strains, as well as the coexistence of chronic illnesses such as diabetes mellitus (DM) greatly aggravate TB morbidity and mortality. DM [particularly type 2 DM (T2DM)] and TB have converged making their control even more challenging. Two contemporary global epidemics, TB-DM behaves like a syndemic, a synergistic confluence of two highly prevalent diseases. T2DM is a risk factor for developing more severe forms of multi-drug resistant-TB and TB recurrence after preventive treatment. Since a bidirectional relationship exists between TB and DM, it is necessary to concurrently treat both, and promote recommendations for the joint management of both diseases. There are also some drug-drug interactions resulting in adverse treatment outcomes in TB-DM patients including treatment failure, and reinfection. In addition, autophagy may play a role in these comorbidities. Therefore, the TB-DM comorbidities present several health challenges, requiring a focus on multidisciplinary collaboration and integrated strategies, to effectively deal with this double burden. To effectively manage the comorbidity, further screening in affected countries, more suitable drugs, and better treatment strategies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.